跳至主要内容
临床试验/NCT02065011
NCT02065011进行中(未招募)2 期

An Open-label Study to Determine the Long-term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B

Sanofi2 个研究点 分布在 2 个国家目标入组 9 人开始时间: 2013年9月12日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
进行中(未招募)
发起方
Sanofi
入组人数
9
试验地点
2
主要终点
The incidence of adverse events

研究概览

简要总结

Primary Objective:

To evaluate the long-term safety and tolerability of SAR421869 in patients with Usher syndrome Type 1B

Secondary Objective:

To assess long-term safety and biological activity of SAR421869

详细描述

The total duration of study period is up to 15 years.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Provide signed and dated written informed consent (and if appropriate assent) and any locally required authorization eg, Health Insurance Portability and Accountability Act (HIPAA).
  • Must have been enrolled in protocol TDU
  • Must have received a subretinal injection of SAR421869

排除标准

  • Did not receive SAR421869 as part of the TDU13600 protocol.

研究组 & 干预措施

Long-term follow up

Other

Long-term follow up of patients who received SAR421869 in a previous study TDU13600

干预措施: Blood draw for the laboratory assessment (Drug)

结局指标

主要结局

The incidence of adverse events

时间窗: 15 years

The number and percentage of patients with treatment emergent adverse events

次要结局

  • Delay in retinal degeneration(baseline to 15 years)
  • Clinically important changes in ocular safety assessments(baseline to 15 years)

研究者

发起方
Sanofi
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

A Study to Determine the Long-Term Safety,... | 临床试验